Brief: Mabion Gets Second Statement Of Work From Novavax

Mabion SA

24/06/2021 08:09

June 24 (Reuters) - Mabion SA  MABP.WA :
    * SAID ON WEDNESDAY IT HAS RECEIVED SECOND STATEMENT OF WORK
FROM
NOVAVAX UNDER FRAMEWORK DEAL
    * STATEMENT ENABLES COMPANY TO MAKE EARLIER ORDERS FOR KEY
RAW
MATERIALS FOR PRODUCTION UNDER BUDGET AGREED WITH AND FINANCED
BY NOVAVAX
    * STATEMENT REGARDS ORDERING RAW MATERIAL VOLUMES WHICH WILL
ENABLE CARRYING OUT COMMERCIAL PROCESS OF PRODUCING ACTIVE
INGREDIENT FOR NOVAVAX COVID-19 VACCINE CANDIDATE USING
COMPANY'S FULL PRODUCTION CAPACITY TILL END OF 2022 ACCORDING TO
COMPANY'S ESTIMATES
    * COMPANY WILL RECEIVE FULL PREPAYMENT FROM NOVAVAX FOR
CARRYING
OUT RAW MATERIALS ORDER
    * SIGNING OF PRODUCTION AGREEMENT STILL REQUIRES
SPECIFICATION OF
TECHNICAL, FINANCIAL, QUALITY AND SCHEDULE ASPECTS BY PARTIES
AND DEPENDS MAINLY ON POSITIVE EXECUTION OF FIRST ORDER
    * SIGNING SECOND STATEMENT OF WORK DOES NOT DETERMINE
WHETHER
PRODUCTION AGREEMENT WILL BE CONCLUDED

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nEM5YylvQa
    
 Further company coverage:  MABP.WA  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))